Blue Matter Blog

Expanding a Biotech Business into Europe: Determining Which Model to Use When Launching Your First Product and Building Country Operations in Europe
July 22, 2021

The biotechnology industry is a booming sector with many new companies researching and developing innovative and specialized medicines. Typically, a startup biotech company will focus its limited resources on R&D and its market of origin (or some other region that’s strategically selected because of its large size and/or market potential).  For a US-based company, that …

How will the change to a more narrow FDA label for Aduhelm (aducanumab) help Biogen?
July 14, 2021

Varun Renjen, M.D. describes how the recent decision to restrict Aduhelm’s label to earlier-stage patients with mild cognitive impairment (MCI) could be a good thing for Biogen’s new Alzheimer’s therapy. He also outlines three lessons for other pharma companies entering the Alzheimer’s market. Link here

Keeping Biopharma Up At Night: How the Chronic Insomnia Market Raises Big Questions About Digital Therapeutics
July 9, 2021

The Digital Therapeutics (DTx) space is new and rapidly growing within the healthcare landscape (for a DTx 101: Intro and Overview, see here).  Biopharma companies should carefully consider their potential entry into this space, as their customers will be increasingly engaging with DTx products that have the potential to complement or even compete with biopharma …